RCAR - RenovaCare, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

RenovaCare, Inc.

430 Park Avenue
Suite 702
New York, NY 10022
United States

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Thomas BoldPres, CEO, Interim CFO, Principal Accounting Officer & Director100kN/A1961
Mr. Joseph SierchioSec. & DirectorN/AN/A1949
Ms. Patsy J. TrislerVP of Regulatory & Clinical Affairs60kN/A1948
Mr. Andrew DanielsonDirector of OperationsN/AN/AN/A
Dr. Roger Esteban-VivesDirector of Cell SciencesN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


RenovaCare, Inc., a development-stage company, focuses on the acquisition, research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. Its flagship technology product is CellMist System, which include a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. The company was formerly known as Janus Resources, Inc. and changed its name to RenovaCare, Inc. in January 2014. RenovaCare, Inc. is based in New York, New York.

Corporate Governance

RenovaCare, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.